Drugs Made In America Acquisition (DMII) Total Non-Current Liabilities (2025)

Drugs Made In America Acquisition (DMII) reported Total Non-Current Liabilities of $17.5 million for Q4 2025.

Drugs Made In America Acquisition (DMII) Total Non-Current Liabilities (2025) Analysis & Trends

Drugs Made In America Acquisition (DMII) has 1 years of Total Non-Current Liabilities data on file, last reported at $17.5 million in Q4 2025.

  • Total Non-Current Liabilities for Q4 2025 came in at $17.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $17.5 million (changed N/A YoY), and the FY2025 annual result was $17.5 million, changed N/A from the prior year.
  • Total Non-Current Liabilities held at $17.5 million in Q4 2025 per DMII's latest filing.
  • Over five years, Total Non-Current Liabilities peaked at $17.5 million in Q4 2025 and troughed at $17.5 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 EQV Ventures Acquisition 477.93 Mn 477.93 Mn - -
2 GP-Act III Acquisition 312.80 Mn 312.80 Mn - -
3 Berto Acquisition 311.56 Mn 311.56 Mn - -
4 Churchill Capital Corp IX 310.79 Mn 310.79 Mn - -
5 Centurion Acquisition 310.21 Mn 310.21 Mn - -
6 WEN Acquisition 309.15 Mn 309.15 Mn - -
7 Agriculture & Natural Solutions Acquisition 303.81 Mn 303.81 Mn - 29.40 Mn
8 Bold Eagle Acquisition 274.64 Mn 274.64 Mn - -
9 Live Oak Acquisition Corp. V 265.88 Mn 265.88 Mn - -
10 Drugs Made In America Acquisition 129.34 Mn 129.34 Mn - 17.50 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 17.50 Mn